Compare Stocks: LGVN, YARW, SERA, and CRDF

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRDF Cardiff Oncology	$1.09 +0.9%	$1.02	$0.76 ▼ $3.31	$84.80M	1.46	697,685 shs	437,324 shs
LGVN Longeveron	$6.81 +3.5%	$6.91	$4.75 ▼ $12.30	$20.98M	-0.25	76,661 shs	40,353 shs
SERA Sera Prognostics	$2.02 +2.0%	$2.04	$1.56 ▼ $3.95	$78.11M	0.98	24,540 shs	10,533 shs
YARW Yarrow Bioscience	$30.21 +4.7%	$0.00	$14.02 ▼ $46.95	$77.02M	2.01	35,638 shs	26,577 shs

Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRDF Cardiff Oncology	+0.93%	+15.96%	+14.14%	-27.33%	-44.39%
LGVN Longeveron	+3.50%	+1.34%	-6.34%	-6.71%	-16.53%
SERA Sera Prognostics	+2.02%	-2.42%	+1.00%	-11.79%	-40.59%
YARW Yarrow Bioscience	+4.71%	-18.35%	-19.87%	+3,020,999,900.00%	+3,020,999,900.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRDF Cardiff Oncology	$1.09 +0.9%	$1.02	$0.76 ▼ $3.31	$84.80M	1.46	697,685 shs	437,324 shs
LGVN Longeveron	$6.81 +3.5%	$6.91	$4.75 ▼ $12.30	$20.98M	-0.25	76,661 shs	40,353 shs
SERA Sera Prognostics	$2.02 +2.0%	$2.04	$1.56 ▼ $3.95	$78.11M	0.98	24,540 shs	10,533 shs
YARW Yarrow Bioscience	$30.21 +4.7%	$0.00	$14.02 ▼ $46.95	$77.02M	2.01	35,638 shs	26,577 shs

Don't Wait for the OpenAI IPO

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRDF Cardiff Oncology	+0.93%	+15.96%	+14.14%	-27.33%	-44.39%
LGVN Longeveron	+3.50%	+1.34%	-6.34%	-6.71%	-16.53%
SERA Sera Prognostics	+2.02%	-2.42%	+1.00%	-11.79%	-40.59%
YARW Yarrow Bioscience	+4.71%	-18.35%	-19.87%	+3,020,999,900.00%	+3,020,999,900.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRDF Cardiff Oncology	2.14	Hold	$7.50	588.07% Upside
LGVN Longeveron	2.00	Hold	$80.00	1,074.74% Upside
SERA Sera Prognostics	2.67	Moderate Buy	$5.50	172.28% Upside
YARW Yarrow Bioscience	2.33	Hold	$58.00	91.99% Upside

Current Analyst Ratings Breakdown

Latest LGVN, YARW, SERA, and CRDF Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/25/2026	LGVN Longeveron	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/19/2026	CRDF Cardiff Oncology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/11/2026	CRDF Cardiff Oncology	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
8/11/2026	LGVN Longeveron	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/5/2026	CRDF Cardiff Oncology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/3/2026	YARW Yarrow Bioscience	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Hold ➝ Buy	$58.00
7/31/2026	SERA Sera Prognostics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/28/2026	LGVN Longeveron	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/28/2026	YARW Yarrow Bioscience	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy
7/21/2026	CRDF Cardiff Oncology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/16/2026	SERA Sera Prognostics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 9/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRDF Cardiff Oncology	$508K	166.92	N/A	N/A	$0.34 per share	3.21
LGVN Longeveron	$1.20M	18.10	N/A	N/A	$3.26 per share	2.09
SERA Sera Prognostics	$80K	996.11	N/A	N/A	$1.51 per share	1.34
YARW Yarrow Bioscience	$570K	141.51	N/A	N/A	$8.26 per share	3.66

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRDF Cardiff Oncology	-$45.85M	-$0.60	N/A	N/A	N/A	-7,885.43%	-103.10%	-75.52%	11/5/2026 (Estimated)
LGVN Longeveron	-$22.70M	-$9.90	N/A	N/A	N/A	-1,977.59%	-223.19%	-150.20%	11/3/2026 (Estimated)
SERA Sera Prognostics	-$31.93M	-$0.67	N/A	N/A	N/A	-47,475.72%	-46.71%	-34.06%	11/12/2026 (Estimated)
YARW Yarrow Bioscience	-$26.48M	-$14.64	N/A	N/A	N/A	-4,726.21%	-84.40%	-77.68%	N/A

Latest LGVN, YARW, SERA, and CRDF Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	YARW Yarrow Bioscience	-$0.18	-$3.51	-$3.33	-$3.51	$0.20 million	$0.10 million
8/12/2026	Q2 2026	LGVN Longeveron	-$1.75	-$1.90	-$0.15	-$0.19	$0.33 million	$0.29 million
8/12/2026	Q2 2026	SERA Sera Prognostics	-$0.1542	-$0.18	-$0.0258	-$0.18	$0.07 million	$0.03 million
8/11/2026	Q2 2026	CRDF Cardiff Oncology	-$0.1196	-$0.14	-$0.0204	-$0.14	$0.06 million	$0.10 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRDF Cardiff Oncology	N/A	N/A	N/A	N/A	N/A
LGVN Longeveron	N/A	N/A	N/A	N/A	N/A
SERA Sera Prognostics	N/A	N/A	N/A	N/A	N/A
YARW Yarrow Bioscience	N/A	N/A	N/A	N/A	N/A

Latest LGVN, YARW, SERA, and CRDF Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/10/2026	YARW Yarrow Bioscience	special	$19.00			7/22/2026	7/23/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRDF Cardiff Oncology	N/A	3.30	3.30
LGVN Longeveron	N/A	2.63	2.63
SERA Sera Prognostics	N/A	1.98	1.98
YARW Yarrow Bioscience	N/A	15.26	15.26

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRDF Cardiff Oncology	16.29%
LGVN Longeveron	10.01%
SERA Sera Prognostics	54.64%
YARW Yarrow Bioscience	83.78%

Insider Ownership

Company	Insider Ownership
CRDF Cardiff Oncology	8.80%
LGVN Longeveron	7.42%
SERA Sera Prognostics	11.30%
YARW Yarrow Bioscience	3.03%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRDF Cardiff Oncology	20	77.80 million	70.95 million	Optionable
LGVN Longeveron	20	3.19 million	2.95 million	Not Optionable
SERA Sera Prognostics	120	39.45 million	34.99 million	Optionable
YARW Yarrow Bioscience	30	2.67 million	2.59 million	N/A

LGVN, YARW, SERA, and CRDF Headlines

Recent News About These Companies

Yarrow Bioscience’s YB-101 Trial Targets Graves’ Disease, Raising New Investor Interest

September 4 at 12:31 PM | tipranks.com

Yarrow Bioscience (NASDAQ:YARW) Sees Large Growth in Short Interest

September 3 at 2:22 AM | americanbankingnews.com

Analyst Maintains Buy on Yarrow Bioscience, Sees Attractive Risk-Reward with Unchanged $56 Price Target

August 13, 2026 | tipranks.com

Yarrow Bioscience Alters Capital Structure With Warrant Exchange

July 30, 2026 | tipranks.com

Yarrow Bioscience Completes VYNE Therapeutics Merger, Begins Phase 2 Trial Dosing for YB-101

July 29, 2026 | finance.yahoo.com

Yarrow Bioscience Announces Closing of Merger with VYNE Therapeutics and Initiation of Dosing in Phase 2a/2b Trial of YB-101, a Potential First-in-Class Treatment for Graves ...

July 27, 2026 | finance.yahoo.com

VYNE Therapeutics Provides Update Regarding Cash Dividend, Reverse Stock Split and Anticipated Timing of Closing of the Proposed Merger with Yarrow Bioscience

July 23, 2026 | globenewswire.com

VYNE Therapeutics Inc.: VYNE Therapeutics Announces 1-for-50 Reverse Stock Split and Provides Update Regarding Special Dividend in Connection with the Proposed Merger with ...

July 22, 2026 | finanznachrichten.de

VYNE Therapeutics (NASDAQ:VYNE) Draws Technical Attention After Reverse Split Update

July 22, 2026 | kalkinemedia.comK

VYNE Therapeutics Announces 1-for-50 Reverse Stock Split and Provides Update Regarding Special Dividend in Connection with the Proposed Merger with Yarrow Bioscience

July 21, 2026 | globenewswire.com

Vyne Therapeutics (NASDAQ:VYNE): What’s Behind the Special Dividend?

July 10, 2026 | kalkinemedia.comK

VYNE Therapeutics Announces Special Cash Dividend in Connection with Pending Merger with Yarrow Bioscience

July 10, 2026 | quiverquant.comQ

VYNE Therapeutics Declares Special Cash Dividend in Connection with the Proposed Merger with Yarrow Bioscience

July 10, 2026 | globenewswire.com

VYNE Therapeutics Insider Trading Activity | NASDAQ:VYNE | Benzinga

July 1, 2026 | benzinga.com

VYNE Therapeutics (VYNE) price target decreased by 38.46% to 2.04

May 15, 2026 | msn.com

Shareholder Alert: The Ademi Firm investigates whether VYNE Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders

December 18, 2025 | prnewswire.com

3 penny stocks to watch now, 12/18/25

December 18, 2025 | msn.com

VYNE to merge with Yarrow in $200 million deal

December 18, 2025 | thepharmaletter.comT

Roundup: Harbor BioMed Announces Collaboration and License Agreement with Bristol Myers, Squibb, VYNE Therapeutics Enters Merger Agreement with Yarrow Bioscience

December 17, 2025 | pharmexec.comP

$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of VYNE Therapeutics Inc. (NASDAQ: VYNE)

December 17, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LGVN, YARW, SERA, and CRDF Company Descriptions

Cardiff Oncology NASDAQ:CRDF

$1.09 +0.01 (+0.93%)

As of 09/4/2026 04:00 PM Eastern

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Longeveron NASDAQ:LGVN

$6.81 +0.23 (+3.50%)

As of 09/4/2026 04:00 PM Eastern

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida.

Sera Prognostics NASDAQ:SERA

$2.02 +0.04 (+2.02%)

As of 09/4/2026 04:00 PM Eastern

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

Yarrow Bioscience NASDAQ:YARW

$30.21 +1.36 (+4.71%)

As of 09/4/2026 04:00 PM Eastern

VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LGVN, YARW, SERA, and CRDF Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LGVN, YARW, SERA, and CRDF Earnings

Compare Dividends

Latest LGVN, YARW, SERA, and CRDF Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LGVN, YARW, SERA, and CRDF Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

LGVN, YARW, SERA, and CRDF Company Descriptions

Cardiff Oncology NASDAQ:CRDF

Longeveron NASDAQ:LGVN

Sera Prognostics NASDAQ:SERA

Yarrow Bioscience NASDAQ:YARW

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LGVN, YARW, SERA, and CRDF Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LGVN, YARW, SERA, and CRDF Earnings

Compare Dividends

Latest LGVN, YARW, SERA, and CRDF Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LGVN, YARW, SERA, and CRDF Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

LGVN, YARW, SERA, and CRDF Company Descriptions

Cardiff Oncology NASDAQ:CRDF

Longeveron NASDAQ:LGVN

Sera Prognostics NASDAQ:SERA

Yarrow Bioscience NASDAQ:YARW

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools